Needham analyst Anna Andreeva initiates coverage on Poshmark (NASDAQ:POSH) with a Hold rating.
BeiGene Announces First Patient Dosed in Global Phase 3 Trial of Anti-TIGIT Antibody Ociperlimab in Non-Small Cell Lung Cancer
BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160)), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the first patient was dosed in the global Phase 3